Cardio Diagnostics Holdings (NASDAQ: CDIO) took center stage in the latest episode of The BioMedWire Podcast, where CEO and Co-Founder Dr. Meesha Dogan discussed the company's mission to improve cardiovascular disease prevention and early detection through precision medicine powered by epigenetics, genetics, and artificial intelligence. During the interview, Dogan highlighted Cardio Diagnostics' expansion into India through partnerships with Aimil Ltd. and Dr. Lal PathLabs, as well as the company's progress through the Medicare reimbursement process, noting that CPT coding and payment steps have been completed while coverage determination remains underway.
The company's core technology, an AI-driven Integrated Genetic-Epigenetic Engine, aims to make cardiovascular disease prevention, detection, and management more accessible and personalized. This approach leverages advanced biomarkers to identify individuals at risk earlier than traditional methods, potentially reducing the burden of heart disease globally. The expansion into India represents a significant milestone, as the country faces a rising prevalence of cardiovascular conditions. Partnerships with established diagnostic firms like Aimil Ltd. and Dr. Lal PathLabs are expected to facilitate the distribution of Cardio Diagnostics' tests across the Indian healthcare system.
Dr. Dogan also provided updates on the regulatory and reimbursement front. The completion of CPT coding and payment steps is a crucial step toward broader adoption in the U.S. healthcare market. However, coverage determination by Medicare is still pending, which will ultimately dictate the accessibility of these tests for beneficiaries. The company's progress in this area underscores the potential for precision medicine to become a standard part of cardiovascular care.
Cardio Diagnostics is positioned as a leader in the precision cardiovascular medicine space, aiming to transform how heart disease is prevented and managed. The company's focus on integrating genetics, epigenetics, and AI sets it apart in a competitive landscape. As it continues to advance both domestically and internationally, the implications for public health are substantial. Earlier detection could lead to better outcomes and reduced healthcare costs.
For more details on the podcast and Cardio Diagnostics' initiatives, the full press release is available at https://ibn.fm/8DJcl. Investors seeking the latest updates on CDIO can visit the company's newsroom at https://ibn.fm/CDIO.
